Joseph Sparano

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. pmc Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer
    Joseph A Sparano
    Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
    Cancer 118:5937-46. 2012
  2. pmc Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial
    Joseph A Sparano
    Albert Einstein College of Medicine, Montefiore Medical Center Weiler Division, 1825 Eastchester Rd, 2S Rm 47, Bronx, NY 10461, USA
    J Natl Cancer Inst 104:406-14. 2012
  3. ncbi request reprint Clinical application of molecular profiling in breast cancer
    Joseph A Sparano
    Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Room 47, 1825 Eastchester Road, 2 South, Bronx, NY 10461, USA
    Future Oncol 1:485-96. 2005
  4. ncbi request reprint Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide
    Joseph A Sparano
    New York Phase II Consortium, Albert Einstein Cancer Center, Montefiore Medical Center Weiler Division, Department of Oncology, 2 S, Room 47 48, 1825 Eastchester Rd, Bronx, NY 10461, USA
    J Clin Oncol 24:3013-8. 2006
  5. ncbi request reprint TAILORx: trial assigning individualized options for treatment (Rx)
    Joseph A Sparano
    Albert Einstein College of Medicine, Breast Evaluation Center, Montefiore Medical Center, Bronx, NY 10461, USA
    Clin Breast Cancer 7:347-50. 2006
  6. doi request reprint Development of the 21-gene assay and its application in clinical practice and clinical trials
    Joseph A Sparano
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Clin Oncol 26:721-8. 2008
  7. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
  8. pmc Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
    Joseph A Sparano
    New York Cancer Consortium, including the Montefiore Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA
    Clin Cancer Res 15:2942-8. 2009
  9. doi request reprint Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin
    Joseph A Sparano
    Montefiore Einstein Cancer Center, 1825 Eastchester Rd, Bronx, NY 10461, USA
    J Clin Oncol 27:4522-9. 2009
  10. pmc Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
    Joseph A Sparano
    Montefiore Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10461, USA
    Blood 115:3008-16. 2010

Research Grants

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2006
  2. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
  3. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2007

Detail Information

Publications55

  1. pmc Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer
    Joseph A Sparano
    Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
    Cancer 118:5937-46. 2012
    ..Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated...
  2. pmc Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial
    Joseph A Sparano
    Albert Einstein College of Medicine, Montefiore Medical Center Weiler Division, 1825 Eastchester Rd, 2S Rm 47, Bronx, NY 10461, USA
    J Natl Cancer Inst 104:406-14. 2012
    ..We evaluated associations between black race and outcomes, by tumor hormone receptor and HER2 expression, in patients who were treated with contemporary adjuvant therapy...
  3. ncbi request reprint Clinical application of molecular profiling in breast cancer
    Joseph A Sparano
    Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Room 47, 1825 Eastchester Road, 2 South, Bronx, NY 10461, USA
    Future Oncol 1:485-96. 2005
    ..The completion of these important studies will represent the first step toward integrating molecular profiling into treatment selection for adjuvant therapy in breast cancer...
  4. ncbi request reprint Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide
    Joseph A Sparano
    New York Phase II Consortium, Albert Einstein Cancer Center, Montefiore Medical Center Weiler Division, Department of Oncology, 2 S, Room 47 48, 1825 Eastchester Rd, Bronx, NY 10461, USA
    J Clin Oncol 24:3013-8. 2006
    ....
  5. ncbi request reprint TAILORx: trial assigning individualized options for treatment (Rx)
    Joseph A Sparano
    Albert Einstein College of Medicine, Breast Evaluation Center, Montefiore Medical Center, Bronx, NY 10461, USA
    Clin Breast Cancer 7:347-50. 2006
  6. doi request reprint Development of the 21-gene assay and its application in clinical practice and clinical trials
    Joseph A Sparano
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Clin Oncol 26:721-8. 2008
    ....
  7. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  8. pmc Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer
    Joseph A Sparano
    New York Cancer Consortium, including the Montefiore Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA
    Clin Cancer Res 15:2942-8. 2009
    ....
  9. doi request reprint Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin
    Joseph A Sparano
    Montefiore Einstein Cancer Center, 1825 Eastchester Rd, Bronx, NY 10461, USA
    J Clin Oncol 27:4522-9. 2009
    ....
  10. pmc Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
    Joseph A Sparano
    Montefiore Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10461, USA
    Blood 115:3008-16. 2010
    ..We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma...
  11. doi request reprint Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy
    Joseph A Sparano
    Montefiore Medical Center Weiler Division, Professor of Medicine and Women s Health, Albert Einstein College of Medicine, 1825 Eastchester Road, 10461, Bronx, NY, USA
    Breast Cancer Res Treat 120:273-84. 2010
    ..Ongoing and future trials will further refine optimal locoregional management, and additional research is required to develop improved screening methods and identify high risk populations most likely to benefit from targeted screening...
  12. doi request reprint Clinical application of gene expression profiling in breast cancer
    Joseph A Sparano
    Department of Medicine and Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, 1825 Eastchester Road, Bronx, NY 10461, USA
    Surg Oncol Clin N Am 19:581-606. 2010
    ..Several multiparameter gene expression assays are commercially available, and additional assays are being developed that will facilitate more accurate therapeutic individualization...
  13. pmc Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
    Joseph A Sparano
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 17:7194-203. 2011
    ..To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy...
  14. ncbi request reprint HIV-associated lymphoma: the evidence for treating aggressively but with caution
    Joseph A Sparano
    Albert Einstein College of Medicine, Department of Oncology, Montefiore Medical Center, Weiler Division, Bronx, New York 10461, USA
    Curr Opin Oncol 19:458-63. 2007
    ..The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year...
  15. ncbi request reprint Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)
    Joseph A Sparano
    Albert Einstein Cancer Center and Montefiore Medical Center, Weiler Division, 1825 Eastchester Road 2 South, Rm 47 48, Bronx, NY 10461, USA
    J Clin Oncol 22:1491-500. 2004
    ..To determine the effectiveness of an infusional chemotherapy regimen in patients with HIV-associated lymphoma treated before and after the use of highly active antiretroviral therapy (HAART) in routine clinical practice...
  16. ncbi request reprint Human immunodeficiency virus associated lymphoma
    Joseph A Sparano
    Albert Einstein College of Medicine and Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA
    Curr Opin Oncol 15:372-8. 2003
    ..The purpose of this review is to highlight recent advances in the diagnosis and management of lymphoma occurring in patients with HIV infection...
  17. ncbi request reprint Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers
    Joseph A Sparano
    Department of Oncology, Albert Einstein Cancer Center Montefiore Medical Center, Bronx, New York 10461, USA
    Drug Saf 25:301-11. 2002
    ..Clinical trials are currently evaluating the role of these markers in predicting both early and late, clinical and subclinical damage associated with anthracyclines and trastuzumab...
  18. pmc Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Joseph A Sparano
    Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Clin Oncol 28:3256-63. 2010
    ....
  19. ncbi request reprint AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles
    Rashna Madan
    Department of Pathology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY 10467, USA
    Mod Pathol 19:438-46. 2006
    ..We report the new finding that the AIDS status of the patient predicts the immunophenotype of the diffuse large B-cell lymphomas...
  20. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  21. ncbi request reprint Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes
    Huda S Salman
    Department of Oncology, Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Bronx, NY, USA
    Clin Breast Cancer 2:299-303. 2002
    ..This regimen is not likely to produce more than a 40% response rate in patients with metastatic breast cancer previously treated with taxanes...
  22. ncbi request reprint Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer
    Joshua P Raff
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York, NY 10461 2373, USA
    Clin Breast Cancer 4:420-7. 2004
    ..Weekly docetaxel may be effective in as many as 20% of patients who had progressive disease after treatment with taxanes given every 3 weeks...
  23. doi request reprint Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease
    Janice Diaz
    Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Breast Cancer Res Treat 138:91-7. 2013
    ..21, 95 % CI [2.19, 57.37]; p = 0.004). Our findings indicated that evaluation of MC after NST warrants validation and further evaluation as a prognostic marker in breast cancer...
  24. ncbi request reprint Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma
    Joseph A Sparano
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461 2373, USA
    Med Oncol 22:257-67. 2005
    ..5 mg/m2/d) (CDE) given every 28 d plus granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with poor prognosis non-Hodgkin's lymphoma (Group A), and the same regimen given every 21 d (Group B)...
  25. pmc Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment
    Stephanie V Blank
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA
    Gynecol Oncol 119:451-6. 2010
    ....
  26. doi request reprint Farnesyl transferase inhibitors
    Tianhong Li
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, New York, New York, USA
    Cancer Invest 26:653-61. 2008
  27. ncbi request reprint A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma
    Della Makower
    Department of Oncology, Montefiore Medical Center Albert Einstein Cancer Center, 111 E 210 Street, Bronx, NY 10467, USA
    Cancer Invest 21:177-84. 2003
    ..5 weeks (range 14.5-28+). Edrecolomab and capecitabine may be safely given in combination to patients with advanced or metastatic adenocarcinoma. Clinical activity is seen in this heavily pretreated patient population...
  28. ncbi request reprint Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196
    Joseph A Sparano
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10461, USA
    J Clin Oncol 22:4683-90. 2004
    ..To determine whether a matrix metalloproteinase inhibitor improves progression-free survival (PFS) in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy...
  29. ncbi request reprint Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)
    Joseph A Sparano
    Albert Einstein Comprehensive Cancer Center Montefiore Medical Center, Bronx, NY, USA
    Blood 100:1634-40. 2002
    ..It is unlikely that infusional therapy as used in this study produces a 25% or greater relative improvement in FFS compared with standard therapy...
  30. ncbi request reprint Inhibiting Ras signaling in the therapy of breast cancer
    Tianhong Li
    Albert Einstein Cancer Center, Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA
    Clin Breast Cancer 3:405-16; discussion 417-20. 2003
    ..Clinical trials are currently underway evaluating whether these agents have a useful role in the management of advanced breast cancer...
  31. ncbi request reprint Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum
    Samir Parekh
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA
    J Clin Oncol 23:8116-7. 2005
  32. doi request reprint Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
    Sunil S Badve
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:2473-81. 2008
    ....
  33. ncbi request reprint Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma
    Huda Salman
    Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA
    Am J Clin Oncol 26:338-43. 2003
    ..Substitution of idarubicin for doxorubicin in this setting, therefore, is not associated with an improved response rate...
  34. pmc A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma
    Rachel Raab
    Department of Oncology, Montefiore Einstein Cancer Center, New York Cancer Consortium Coordinating Center, Bronx, New York 10461, USA
    Am J Clin Oncol 33:61-5. 2010
    ..To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma...
  35. ncbi request reprint Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma
    Muhammad R Abbasi
    Department of Medicine, Jacobi Medical Center, Bronx, NY, USA
    Med Oncol 20:53-8. 2003
    ..Further study will be required in order to determine whether the fludarabine paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia..
  36. pmc Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma
    Anthony P Lam
    New York Cancer Consortium www newyorkcancerconsortium org, including the Montefiore Einstein Cancer Center, Bronx, NY 10461, USA
    Am J Clin Oncol 33:121-4. 2010
    ..To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma...
  37. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
    ..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features...
  38. ncbi request reprint Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:1206-11. 2004
    ..The portfolio of Eastern Cooperative Oncology Group studies will serve to further define the role of this therapeutic strategy for patients with advanced cancer...
  39. ncbi request reprint Metastatic carcinoma: an unusual cause of focal brain lesions in HIV infection
    Anu G Gaba
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    AIDS Read 13:547-8, 551-3, 558-9. 2003
    ..Brain biopsy may be indicated, however, in select cases that do not meet these criteria in order to identify potentially treatable infections and PCNSL...
  40. ncbi request reprint Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center
    Kylie A Hotchkiss
    Department of Oncology, Albert Einstein College of Medicine, Bronx, New York 10467, USA
    Mol Cancer Ther 1:1191-200. 2002
    ..In conclusion, Taxotere is a potent and potentially specific inhibitor of endothelial cell migration in vitro and angiogenesis in vitro and in vivo...
  41. ncbi request reprint Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases
    Robert P Gormley
    Department of Pathology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Am J Clin Pathol 124:790-8. 2005
    ..This revealed a high-GC/low-ABC group and a low-GC/high-ABC group that were associated significantly with morphologic diagnosis (P < .001). Protein expression of multiple GC and ABC markers can separate BL and DLBCL...
  42. ncbi request reprint Human immunodeficiency virus-associated lymphoma
    Samir Parekh
    Albert Einstein College of Medicine, USA
    Clin Adv Hematol Oncol 1:295-301. 2003
    ..There are anecdotal reports of responses to therapy directed against Epstein-Barr virus (ie, high-dose zidovudine, gancyclovir, and interleukin-2)...
  43. pmc Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status
    Tianhong Li
    Department of Cancer Biology, Kimmel Cancer Center, Bluemle Life Sciences Building, Room 933, 233 S 10th Street, Philadelphia, PA 19107, USA
    Am J Pathol 168:1998-2013. 2006
    ..Finally, we discuss the possibility that sporadic Cav-1 mutations may act as an initiating event in human breast cancer pathogenesis...
  44. ncbi request reprint Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life
    Alyson B Moadel
    Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx, NY 10461, USA
    J Clin Oncol 25:4387-95. 2007
    ..This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients...
  45. ncbi request reprint Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection
    Michele Spina
    AIDS 17:137-8. 2003
  46. ncbi request reprint Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma
    John P Leonard
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 13:6168-74. 2007
    ..This Phase I trial was designed to investigate the safety, tolerability, and preliminary antitumor activity of PF-3512676 in combination with rituximab...
  47. ncbi request reprint Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
    David S Alberts
    The Arizona Cancer Center, Tucson, AZ, USA
    Semin Oncol 31:53-90. 2004
    ....
  48. ncbi request reprint The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
    Nicholas J Robert
    The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
    Semin Oncol 31:106-46. 2004
    ..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
  49. pmc Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
    Lawrence D Kaplan
    Division of Hematology Oncology, University of California, 400 Parnassus Ave, Rm A 502, San Francisco, CA 94143, USA
    Blood 106:1538-43. 2005
    ..However, these benefits may be offset by an increase in infectious deaths, particularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3)...
  50. ncbi request reprint Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer
    Ruth M O'Regan
    Hematology Oncology, Emory University School of Medicine, Translational Breast Cancer Research Program, Winship Cancer Institute, Atlanta, GA, USA
    Clin Breast Cancer 6:163-8. 2005
    ..The objective of this study was to determine the pCR rate in patients with stage III breast cancer treated with 4 cycles of TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2) on day 1 before surgery...
  51. ncbi request reprint A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, Indiana, USA
    Clin Cancer Res 10:1971-5. 2004
    ..This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase inhibitor (MMPI), into adjuvant breast cancer therapy...
  52. ncbi request reprint Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196
    Stanley Zucker
    Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
    Clin Breast Cancer 6:525-9. 2006
    ....
  53. ncbi request reprint Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  54. ncbi request reprint Cancer in AIDS
    Joseph A Sparano
    Curr Opin Oncol 17:446. 2005
  55. ncbi request reprint Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
    Michele Spina
    Division of Medical Oncology A, National Cancer Institute, Via Pedemontana Occidentale 12, 33081, Aviano PN Italy
    Blood 105:1891-7. 2005
    ..Further studies evaluating rituximab in combination with infusional chemotherapy are warranted, but caution is advised...

Research Grants4

  1. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2006
    ....
  2. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  3. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2007
    ....